Source: Annual Congress 2005 - COPD - diagnosis and staging III
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Makris, J. Moschandrea, N. Tzanakis, M. Kokkosi, E. Ntaoukakis, N. M. Siafakas (Heraklion, Chania, Greece). Frequent exacerbations in ex smokers with COPD are associated with accelerated rate of FEV₁ decline. Eur Respir J 2005; 26: Suppl. 49, 3327

Member's Comments

No comment yet.

Related content which might interest you: Frequent exacerbations in COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 Regular follow-up in severe asthma may reduce the rate of exacerbations and the FEV1 decline Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011 Decline in FEV1 is faster with frequent exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 Biomarkers to predict FEV1 decline in smokers and early-onset COPD. Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020 Budesonide/formoterol significantly improves lung function and reduces exacerbations in both smokers and ex-smokers with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006 Does Smoking Cessation affect symptoms and FEV1 in smokers with mild COPD? Source: Virtual Congress 2020 – Smoking disease landscape: from inflammation to lung function and comorbidities Year: 2020 Cardiac disease from accelerated FEV1 decline and acute exacerbations: time to rethink comorbidities in COPD Source: Eur Respir J, 57 (3) 2004008; 10.1183/13993003.04008-2020 Year: 2021 Markers of systemic inflammation are associated with increased symptoms and respiratory exacerbations among smokers with preserved spirometry in SPIROMICS Source: International Congress 2018 – Biomarkers in COPD and asthma Year: 2018 Determinants of exacerbation rate in patients with stable COPD Source: Eur Respir J 2004; 24: Suppl. 48, 661s Year: 2004 Tiotropium: COPD exacerbations and decline in FEV1 Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 The evaluation of different factors that cause FEV1 decline in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 135s Year: 2001 Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics Source: Eur Respir J 2003; 21: 95-10 Year: 2003 ADAM33 SNPs are associated with excess FEV1 decline in severe early onset COPD Source: Eur Respir J 2006; 28: Suppl. 50, 582s Year: 2006 FEV1 decline in occupational asthma Source: Eur Respir J 2003; 22: Suppl. 45, 488s Year: 2003 Changes in lung function in patients with acute COPD exacerbations: spirometry vs. forced oscillations Source: Eur Respir J 2001; 18: Suppl. 33, 149s Year: 2001 Both moderate and severe exacerbations accelerate physical activity decline in COPD patients Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017 Year: 2018 Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 FEV1/Height2 could be a better alternative than FEV1 in predicting all cause mortality in patients with COPD Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008